Galapagos Aktie

28,34 EUR +0,18 EUR +0,64 %

17:46:55

STU

28,44 EUR +0,10 EUR +0,35 %

17:50:05

GVIE

Galapagos jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.1,85 Mrd. EUR

KGV23,59Div. Rendite0,00%

WKNA0EAT9

ISINBE0003818359

SymbolGLPGF

Galapagos Aktien News

Sortieren:Datum Meistgelesen

12.06.25GlobeNewswireGalapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

27.05.25GlobeNewswireGalapagos Creates New Subscription Right Plan

14.05.25GlobeNewswireGalapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101

WerbungGalapagos-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

13.05.25GlobeNewswireGalapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes

23.04.25GlobeNewswireGalapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

21.04.25GlobeNewswireGalapagos Announces Executive Leadership Updates

15.04.25GlobeNewswireGalapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025

27.03.25GlobeNewswireGalapagos Publishes 2024 Annual Report and Announces Annual Shareholders’ Meeting

24.02.25GlobeNewswireGalapagos to Present at Upcoming Investor Conferences

17.02.25GlobeNewswireGalapagos receives transparency notification and 13D filing from Tang Capital

12.02.25GlobeNewswireGalapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

08.01.25GlobeNewswireGalapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

07.01.25GlobeNewswireGalapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

07.12.24GlobeNewswireGalapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

05.11.24GlobeNewswireGalapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

30.10.24GlobeNewswireGalapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

07.10.24GlobeNewswireGalapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

30.09.24GlobeNewswireGalapagos receives transparency notification from EcoR1 Capital

16.09.24GlobeNewswireGalapagos receives transparency notification from EcoR1 Capital

03.09.24GlobeNewswireGalapagos receives transparency notification from FMR LLC

23.08.24GlobeNewswireGalapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

20.08.24GlobeNewswireGalapagos receives transparency notification from FMR LLC

01.08.24PR NewswireBridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology

01.08.24GlobeNewswireGalapagos reports half-year 2024 financial results and provides second quarter business update

14.06.24GlobeNewswireGalapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

30.05.24GlobeNewswireGalapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future so

16.05.24GlobeNewswireGalapagos creates new subscription right plans

15.05.24GlobeNewswireGalapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.

02.05.24GlobeNewswireGalapagos reports first quarter 2024 financial results

30.04.24GlobeNewswireGalapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024

04.04.24GlobeNewswireGalapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

28.03.24GlobeNewswireGalapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings

26.03.24GlobeNewswireGalapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

22.02.24GlobeNewswireGalapagos announces full year 2023 results and outlook for 2024

15.02.24GlobeNewswireGalapagos presents at EBMT-EHA annual meeting 2024

31.01.24GlobeNewswireGalapagos completes transaction to transfer Jyseleca® business to Alfasigma

04.01.24GlobeNewswireGalapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.

03.01.24PR NewswireBridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets

03.01.24GlobeNewswireGalapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology

02.01.24GlobeNewswireGalapagos signs agreement to transfer Jyseleca® business to Alfasigma

Galapagos News

Galapagos News: auf dieser Seite finden Sie alle Galapagos News und Nachrichten zur Galapagos Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Galapagos News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Galapagos News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.